326 related articles for article (PubMed ID: 25575713)
1. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
2. uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Dohn LH; Pappot H; Iversen BR; Illemann M; Høyer-Hansen G; Christensen IJ; Thind P; Salling L; von der Maase H; Laerum OD
PLoS One; 2015; 10(8):e0135824. PubMed ID: 26292086
[TBL] [Abstract][Full Text] [Related]
3. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
4. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
5. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry.
Laerum OD; Ovrebo K; Skarstein A; Christensen IJ; Alpízar-Alpízar W; Helgeland L; Danø K; Nielsen BS; Illemann M
Int J Cancer; 2012 Aug; 131(3):558-69. PubMed ID: 21866548
[TBL] [Abstract][Full Text] [Related]
6. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
[TBL] [Abstract][Full Text] [Related]
8. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
11. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
12. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
13. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
15. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Vivani C; Magi S; Mazzucchelli R; Bacchiocchi R; Santinelli A; Muzzonigro G; Blasi F; Montironi R; Fazioli F
Anal Quant Cytol Histol; 2004 Feb; 26(1):15-21. PubMed ID: 15032076
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
[TBL] [Abstract][Full Text] [Related]
19. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
Kim SP; Frank I; Cheville JC; Thompson RH; Weight CJ; Thapa P; Boorjian SA
J Urol; 2012 Aug; 188(2):405-9. PubMed ID: 22704101
[TBL] [Abstract][Full Text] [Related]
20. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
